Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

被引：0
|
作者：
Dan Lu
Chunze Li
Matthew Riggs
Daniel Polhamus
Jonathan French
Priya Agarwal
Shang-Chiung Chen
Shweta Vadhavkar
Monika Patre
Alexander Strasak
Angelica Quartino
Jin Yan Jin
Sandhya Girish
机构：
[1] Genentech,Department of Clinical Pharmacology
[2] Inc.,undefined
[3] Metrum Research Group,undefined
[4] F. Hoffmann-La Roche Ltd.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Trastuzumab emtansine (T-DM1); HER2; Pharmacokinetics; Previously untreated metastatic breast cancer; MARIANNE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：175 / 185
页数：10
相关论文
共 50 条
  • [1] Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
    Lu, Dan
    Li, Chunze
    Riggs, Matthew
    Polhamus, Daniel
    French, Jonathan
    Agarwal, Priya
    Chen, Shang-Chiung
    Vadhavkar, Shweta
    Patre, Monika
    Strasak, Alexander
    Quartino, Angelica
    Jin, Jin Yan
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (01) : 175 - 185
  • [2] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [3] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [4] Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Lu, Dan
    Burris, Howard A., III
    Wang, Bei
    Dees, E. Claire
    Cortes, Javier
    Joshi, Amita
    Gupta, Manish
    Yi, Joo-Hee
    Chu, Yu-Waye
    Shih, Ted
    Fang, Liang
    Girish, Sandhya
    CURRENT DRUG METABOLISM, 2012, 13 (07) : 911 - 922
  • [5] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [6] Metastatic HER2-positive Breast Cancer New Perspectives with Trastuzumab Emtansine (T-DM1)
    Satzger, Ulla
    ONKOLOGIE, 2013, 36 (09): : 525 - 525
  • [7] Exposure-safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC)
    Jin, Jin
    Wang, Bei
    Gao, Yuying
    Samant, Meghan
    Li, Chunze
    Song, Chunyan
    Swain, Sandra M.
    Untch, Michael
    Girish, Sandhya
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer and brain metastases
    Jacot, W.
    Pons, E.
    Guiu, S.
    Levy, C.
    Frenel, J-S
    Bachelot, T.
    D'Hondt, V.
    Firmin, N.
    Romieu, G.
    Thezenas, S.
    Dalenc, F.
    CANCER RESEARCH, 2016, 76
  • [9] Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer
    Akyildiz, Arif
    Ismayilov, Rashad
    Abdurrahimli, Najmaddin
    Ormanci, Aylin
    Guven, Deniz Can
    Tuncel, Murat
    Onur, Mehmet Ruhi
    Aksoy, Sercan
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 100 - 105
  • [10] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Francis W. Hunter
    Hilary R. Barker
    Barbara Lipert
    Françoise Rothé
    Géraldine Gebhart
    Martine J. Piccart-Gebhart
    Christos Sotiriou
    Stephen M. F. Jamieson
    British Journal of Cancer, 2020, 122 : 603 - 612
12345